• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Synchronous Multiple Parathyroid Carcinoma: A Challenging Diagnosis Influencing Optimal Primary Treatment-A Literature Review to Guide Clinical Decision-Making.同步性多发性甲状旁腺癌:一项影响最佳初始治疗的具有挑战性的诊断——指导临床决策的文献综述
J Clin Med. 2025 Jul 24;14(15):5228. doi: 10.3390/jcm14155228.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
-Related Disorders相关疾病
4
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
5
Ophthalmia Neonatorum新生儿眼炎
6
Conservative, physical and surgical interventions for managing faecal incontinence and constipation in adults with central neurological diseases.保守治疗、物理治疗和手术干预用于治疗伴有中枢神经系统疾病的成年人的粪便失禁和便秘。
Cochrane Database Syst Rev. 2024 Oct 29;10(10):CD002115. doi: 10.1002/14651858.CD002115.pub6.
7
Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews.改善消费者安全有效用药的干预措施:系统评价概述
Cochrane Database Syst Rev. 2014 Apr 29;2014(4):CD007768. doi: 10.1002/14651858.CD007768.pub3.
8
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
9
Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.中枢神经系统罕见的非多发性硬化脱髓鞘疾病
Curr Neurol Neurosci Rep. 2025 Jul 1;25(1):45. doi: 10.1007/s11910-025-01432-8.
10
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.

本文引用的文献

1
Chapter 8: Management of aggressive forms of primary HPT: Parathyroid carcinoma and atypical parathyroid tumor.第8章:侵袭性原发性甲状旁腺功能亢进症的管理:甲状旁腺癌和非典型甲状旁腺肿瘤。
Ann Endocrinol (Paris). 2025 Feb;86(1):101697. doi: 10.1016/j.ando.2025.101697. Epub 2025 Jan 14.
2
Efficacy of surufatinib in the treatment of advanced parathyroid carcinoma: A case report.苏鲁法替尼治疗晚期甲状旁腺癌的疗效:一例报告。
Heliyon. 2024 Aug 22;10(17):e36656. doi: 10.1016/j.heliyon.2024.e36656. eCollection 2024 Sep 15.
3
Sporadic Parathyroid Carcinoma Treated With Lenvatinib, Exhibiting a Novel Somatic Mutation.用乐伐替尼治疗的散发性甲状旁腺癌,表现出一种新的体细胞突变。
JCEM Case Rep. 2024 Jul 24;2(8):luae121. doi: 10.1210/jcemcr/luae121. eCollection 2024 Aug.
4
Consensus statement of the European Society of Endocrine Surgeons (ESES) on advanced parathyroid cancer: definitions and management.欧洲内分泌外科学会(ESES)关于晚期甲状旁腺癌的共识声明:定义与管理
Br J Surg. 2024 May 3;111(5). doi: 10.1093/bjs/znae108.
5
Management of surgical diseases of Primary Hyperparathyroidism: indications of the United Italian Society of Endocrine Surgery (SIUEC).原发性甲状旁腺功能亢进症外科疾病的管理:意大利内分泌外科学会(SIUEC)的适应证。
Updates Surg. 2024 Jun;76(3):743-755. doi: 10.1007/s13304-024-01796-5. Epub 2024 Apr 15.
6
A >50% Intraoperative Parathyroid Hormone Level Decrease Into Normal Reference Range Predicts Complete Excision of Malignancy in Patients With Parathyroid Carcinoma.术中甲状旁腺激素水平下降至正常参考范围 >50% 预测甲状旁腺癌患者恶性肿瘤完全切除。
J Surg Res. 2024 Aug;300:567-573. doi: 10.1016/j.jss.2023.11.074. Epub 2023 Dec 27.
7
Parathyroid Retrospective Analysis of Neoplasms Incidence (pTRANI Study): An Italian Multicenter Study on Parathyroid Carcinoma and Atypical Parathyroid Tumour.甲状旁腺肿瘤发病率回顾性分析(pTRANI研究):一项关于甲状旁腺癌和非典型甲状旁腺肿瘤的意大利多中心研究。
J Clin Med. 2023 Sep 29;12(19):6297. doi: 10.3390/jcm12196297.
8
Approach to the Patient With Parathyroid Carcinoma.甲状旁腺癌患者的处理方法。
J Clin Endocrinol Metab. 2023 Dec 21;109(1):256-268. doi: 10.1210/clinem/dgad455.
9
Parathyroid carcinoma: Current management and outcomes - A systematic review.甲状旁腺癌:当前的治疗管理和结局——系统评价。
Am J Otolaryngol. 2023 Jul-Aug;44(4):103843. doi: 10.1016/j.amjoto.2023.103843. Epub 2023 Mar 23.
10
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review.甲状旁腺癌的诊断与管理:最新综述
Endocr Relat Cancer. 2023 Mar 22;30(4). doi: 10.1530/ERC-22-0287. Print 2023 Apr 1.

同步性多发性甲状旁腺癌:一项影响最佳初始治疗的具有挑战性的诊断——指导临床决策的文献综述

Synchronous Multiple Parathyroid Carcinoma: A Challenging Diagnosis Influencing Optimal Primary Treatment-A Literature Review to Guide Clinical Decision-Making.

作者信息

Traini Emanuela, Lanzafame Andrea, Carnassale Giulia, Daloiso Giuseppe, Borghesan Niccolò, Sanchez Alejandro Martin, Mattia Amelia

机构信息

Endocrine Surgery Unit, Ospedale San Carlo di Nancy-GVM Care and Research, 00165 Rome, Italy.

Department of Medical and Surgical Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.

出版信息

J Clin Med. 2025 Jul 24;14(15):5228. doi: 10.3390/jcm14155228.

DOI:10.3390/jcm14155228
PMID:40806850
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12347700/
Abstract

Synchronous multiple parathyroid carcinoma is a rare condition within the already uncommon landscape of parathyroid malignancies, which comprise less than 1% of sporadic primary hyperparathyroidism cases. To date, only seven cases of synchronous multiple parathyroid carcinoma in sporadic primary hyperparathyroidism have been documented. This exceptional rarity complicates both the diagnostic process and therapeutic decision-making. Clinically, parathyroid carcinoma typically presents as a single mass determining severe symptoms. However, no single clinical, biochemical, or imaging feature allows for definitive preoperative diagnosis. Imaging modalities such as ultrasound and sestamibi scans exhibit variable sensitivity and may overlook multi-gland involvement. Histopathological examination remains the only reliable diagnostic method. Management strategies are also controversial: while some advocate for conservative surgery, en bloc resection is generally recommended for its association with improved local control and disease-free survival. Given the exceptional occurrence of synchronous multiple parathyroid carcinoma, there is a lack of standardized protocols for managing parathyroid carcinoma in cases of synchronous and multiple gland involvement. Early multidisciplinary evaluation and individualized treatment planning are therefore crucial. This review aims to synthesize the presently available knowledge about synchronous multiple parathyroid carcinoma, assist clinicians with the limited data available, and discuss the main challenges in the management of this rare entity.

摘要

同步性多发性甲状旁腺癌是在本就罕见的甲状旁腺恶性肿瘤领域中的一种罕见病症,甲状旁腺恶性肿瘤在散发性原发性甲状旁腺功能亢进病例中所占比例不到1%。迄今为止,仅有7例散发性原发性甲状旁腺功能亢进伴同步性多发性甲状旁腺癌的病例被记录在案。这种极其罕见的情况使得诊断过程和治疗决策都变得复杂。临床上,甲状旁腺癌通常表现为单个肿块并引发严重症状。然而,没有单一的临床、生化或影像学特征能够进行明确的术前诊断。超声和甲氧基异丁基异腈扫描等影像学检查方法的敏感性各不相同,可能会忽略多腺体受累情况。组织病理学检查仍然是唯一可靠的诊断方法。治疗策略也存在争议:虽然一些人主张采取保守手术,但鉴于整块切除与改善局部控制和无病生存率相关,一般建议进行整块切除。鉴于同步性多发性甲状旁腺癌的罕见发生情况,对于同步性和多腺体受累的甲状旁腺癌病例,缺乏标准化的管理方案。因此,早期多学科评估和个体化治疗规划至关重要。本综述旨在综合目前关于同步性多发性甲状旁腺癌的现有知识,帮助临床医生应对有限的数据,并讨论这种罕见疾病管理中的主要挑战。